Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy
October 02, 2021 at 22:05 PM EDT
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC). from News Medical Medical Research News Feed https://ift.tt/3uxHUJI https://ift.tt/eA8V8J
